Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis

BACKGROUND: Enzalutamide, a next-generation antiandrogen agent, is approved for the treatment of metastatic castration-resistant prostate cancer (CRPC). While enzalutamide has been shown to improve time to progression and extend overall survival in men with CRPC, the majority of patients ultimately...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahut, Madeline, Fousek, Kristen, Horn, Lucas A, Angstadt, Shantel, Qin, Haiyan, Hamilton, Duane H, Schlom, Jeffrey, Palena, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496692/
https://www.ncbi.nlm.nih.gov/pubmed/37678915
http://dx.doi.org/10.1136/jitc-2023-007386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496692/
https://www.ncbi.nlm.nih.gov/pubmed/37678915
http://dx.doi.org/10.1136/jitc-2023-007386

Ejemplares similares